GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms

키워드

참고문헌 (40)

1. Arber DA, "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia", Blood, 127, pp.2391~2405 (2016)[DOI]
2. Levine RL, "Another piece of the myeloproliferative neoplasms puzzle", N Engl J Med, 369, pp.2451~2452 (2013)[DOI]
3. Vannucchi AM, "Advances in understanding and management of myeloproliferative neoplasms", CA Cancer J Clin, 59, pp.171~191 (2009)[DOI]
4. Cervantes F, "Life expectancy and prognostic factors in the classic BCR", ABL-negative myeloproliferative disorders, 2008, pp.22, 905~914
5. Tefferi A, "Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution", Cancer, 109, pp.2083~2088 (2007)[DOI]
6. Tefferi A, "CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons", Leukemia, 28, pp.1472~1477 (2014)[DOI]
7. Tefferi A, "Myeloproliferative neoplasms: A contemporary review", JAMA Oncol, 1, pp.97~105 (2015)[DOI]
8. Barbui T, "Problems and pitfalls regarding WHO-defined diagnosis of early", prefibrotic primary myelofibrosis versus essential thrombocythemia, 2013, pp.27, 1953~1958
9. Buhr T, "European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis", Haematologica, 97, pp.360~365 (2012)[DOI]
10. Barosi G, "Essential thrombocythemia vs. early", prefibrotic myelofibrosis: why does it matter, 2014, pp.27, 129~140
11. Gisslinger H, "Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria", Leukemia, 30, pp.1126~1132 (2016)[DOI]
12. Barbui T, "Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study", J Clin Oncol, 29, pp.3179~3184 (2011)[DOI]
13. Bjorkholm M, "Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?", Best Pract Res Clin Haematol, 27, pp.141~153 (2014)[DOI]
14. Thiele J, "Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification", Blood, 117, pp.5710~5718 (2011)[DOI]
15. Barbui T, "Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis", Blood Cancer J, 5, pp.e337~ (2015)[DOI]
16. Shimizu R, "GATA-related hematologic disorders", Exp Hematol, 44, pp.696~705 (2016)[DOI]
17. Vannucchi AM, "Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis", Am J Pathol, 167, pp.849~858 (2005)[DOI]
18. Bresnick EH, "Master regulatory GATA transcription factors: mechanistic principles and emerging links to hematologic malignancies", Nucleic Acids Res, 40, pp.5819~5831 (2012)[DOI]
19. Garimella R, "Expression of bone morphogenetic proteins and their receptors in the bone marrow megakaryocytes of GATA-1(low) mice: a possible role in osteosclerosis", J Histochem Cytochem, 55, pp.745~752 (2007)[DOI]
20. Rinaldi CR, "GATA1 is overexpressed in patients with essential thrombocythemia and polycythemia vera but not in patients with primary myelofibrosis or chronic myelogenous leukemia", Leuk Lymphoma, 49, pp.1416~1419 (2008)[DOI]
21. Jaffe ES, "Pathology and genetics of tumours of haematopoietic and lymphoid tissues. 1st ed." (2001), IARC Press; Oxford University Press
22. Swerdlow SH, "WHO classification of tumours of haematopoietic and lymphoid tissues", International Agency for Research on Cancer, ~ (2008)
23. Ponce CC, "The relationship of the active and latent forms of TGF-beta1 with marrow fibrosis in essential thrombocythemia and primary myelofibrosis", Med Oncol, 29, pp.2337~2344 (2012)[DOI]
24. Krajewska M, "Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers", Am J Pathol, 148, pp.1567~1576 (1996)
25. Klampfl T, "Somatic mutations of calreticulin in myeloproliferative neoplasms", N Engl J Med, 369, pp.2379~2390 (2013)[DOI]
26. Rotunno G, "Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia", Blood, 123, pp.1552~1555 (2014)[DOI]
27. Palandri F, "Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis", Leukemia, 29, pp.1344~1349 (2015)[DOI]
28. Edahiro Y, "JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan", Int J Hematol, 99, pp.625~634 (2014)[DOI]
29. Hussein K, "JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis", Exp Hematol, 37, pp.1186~1193 (2009)[DOI]
30. 박상혁, "The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm", Blood Research, 48(2), pp.128~132 (2013), 대한혈액학회
31. Shirane S, "Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia", Int J Hematol, 101, pp.148~153 (2015)[DOI]
32. Yonal-Hindilerden I, "The burden of JAK2V617F mutated allele in Turkish patients with myeloproliferative neoplasms", J Clin Med Res, 7, pp.161~170 (2015)[DOI]
33. Kiladjian JJ, "The spectrum of JAK2-positive myeloproliferative neoplasms", Hematology Am Soc Hematol Educ Program, 2012, pp.561~566 (2012)
34. Larsen TS, "The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype", Eur J Haematol, 79, pp.508~515 (2007)[DOI]
35. Vannucchi AM, "Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal", Leukemia, 22, pp.1299~1307 (2008)[DOI]
36. Vannucchi AM, "Impaired GATA-1 expression and myelofibrosis in an animal model", Pathol Biol (Paris), 52, pp.275~279 (2004)[DOI]
37. Brousseau M, "Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis", Histopathology, 56, pp.758~767 (2010)[DOI]
38. Florena AM, "Value of bone marrow biopsy in the diagnosis of essential thrombocythemia", Haematologica, 89, pp.911~919 (2004)
39. Shimizu R, "Contribution of GATA1 dysfunction to multistep leukemogenesis", Cancer Sci, 103, pp.2039~2044 (2012)[DOI]
40. Shimizu R, "Induction of hyperproliferative fetal megakaryopoiesis by an N-terminally truncated GATA1 mutant", Genes Cells, 14, pp.1119~1131 (2009)[DOI]

관련 논문AI추천